The CTNNBL1 (Catenin Beta Like 1) antibody is a tool used to study the CTNNBL1 protein, a conserved nuclear protein implicated in diverse cellular processes. CTNNBL1 shares structural similarities with β-catenin but lacks canonical Wnt signaling activity. Instead, it interacts with components of the pre-mRNA processing machinery, including the spliceosome, and plays a role in mRNA splicing regulation. It also participates in adipogenesis and lipid metabolism by modulating transcriptional activity, potentially through associations with transcription factors like NF-κB.
Research using CTNNBL1 antibodies has revealed its involvement in diseases, including obesity, cancer, and genetic disorders. For instance, CTNNBL1 mutations are linked to midline cervical cleft (MCC) and muscular dystrophy-dystroglycanopathy type A14 (MDDGA14). In cancer, CTNNBL1 may act as a tumor suppressor or promoter depending on context, influencing pathways like apoptosis and cell proliferation.
Antibodies against CTNNBL1 are utilized in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interaction networks. These studies help unravel CTNNBL1's role in cellular homeostasis, disease mechanisms, and potential therapeutic targeting. Its dual functions in RNA processing and metabolic regulation make it a protein of broad interest in molecular and clinical research.